Dupont Capital Management Corp Increases Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Dupont Capital Management Corp boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 15.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,859 shares of the medical research company’s stock after acquiring an additional 4,328 shares during the period. Thermo Fisher Scientific comprises approximately 1.5% of Dupont Capital Management Corp’s portfolio, making the stock its 16th largest position. Dupont Capital Management Corp’s holdings in Thermo Fisher Scientific were worth $16,910,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TMO. Savant Capital LLC lifted its holdings in Thermo Fisher Scientific by 0.5% during the 4th quarter. Savant Capital LLC now owns 3,627 shares of the medical research company’s stock valued at $1,997,000 after purchasing an additional 18 shares during the last quarter. 1776 Wealth LLC lifted its holdings in Thermo Fisher Scientific by 2.4% during the 4th quarter. 1776 Wealth LLC now owns 799 shares of the medical research company’s stock valued at $440,000 after purchasing an additional 19 shares during the last quarter. Sugarloaf Wealth Management LLC lifted its holdings in Thermo Fisher Scientific by 6.9% during the 4th quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock valued at $156,000 after purchasing an additional 19 shares during the last quarter. Rosenberg Matthew Hamilton lifted its holdings in Thermo Fisher Scientific by 3.7% during the 4th quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock valued at $279,000 after purchasing an additional 19 shares during the last quarter. Finally, Pacifica Partners Inc. lifted its holdings in Thermo Fisher Scientific by 16.5% during the 4th quarter. Pacifica Partners Inc. now owns 141 shares of the medical research company’s stock valued at $69,000 after purchasing an additional 20 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on TMO. Raymond James boosted their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Royal Bank of Canada boosted their target price on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Robert W. Baird reaffirmed an “outperform” rating and issued a $670.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, December 14th. Finally, Citigroup assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They set a “neutral” rating and a $620.00 price target for the company. Five investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $599.00.

Get Our Latest Report on TMO

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock valued at $28,513,384 over the last 90 days. 0.32% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Down 0.9 %

Thermo Fisher Scientific stock opened at $572.03 on Wednesday. The stock has a market capitalization of $218.12 billion, a PE ratio of 37.02, a price-to-earnings-growth ratio of 2.43 and a beta of 0.80. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The company has a 50 day moving average of $566.95 and a 200-day moving average of $521.68.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last released its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, beating the consensus estimate of $5.64 by $0.03. The company had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $5.40 earnings per share. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Friday, March 15th will be given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date is Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is currently 10.10%.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Further Reading

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.